Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVR NASDAQ:LUCD NASDAQ:SMTI NASDAQ:ZYXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVRAnteris Technologies Global$4.87-1.8%$4.42$2.34▼$8.79$178.87MN/A228,510 shs55,098 shsLUCDLucid Diagnostics$1.18-4.1%$1.12$0.75▼$1.80$164.18M1.191.33 million shs597,639 shsSMTISanara MedTech$28.26-3.5%$32.16$23.53▼$39.08$260.84M1.2123,623 shs29,379 shsZYXIZynex$1.33-0.7%$1.51$1.23▼$9.42$40.60M1.174,729 shs101,225 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVRAnteris Technologies Global-1.81%+5.64%-13.19%+59.67%+486,999,900.00%LUCDLucid Diagnostics-4.07%+2.61%+10.28%+5.36%+45.68%SMTISanara MedTech-3.55%-5.36%-17.34%+7.41%-9.71%ZYXIZynex-0.75%-3.62%-11.33%-42.42%-83.14%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVRAnteris Technologies Global$4.87-1.8%$4.42$2.34▼$8.79$178.87MN/A228,510 shs55,098 shsLUCDLucid Diagnostics$1.18-4.1%$1.12$0.75▼$1.80$164.18M1.191.33 million shs597,639 shsSMTISanara MedTech$28.26-3.5%$32.16$23.53▼$39.08$260.84M1.2123,623 shs29,379 shsZYXIZynex$1.33-0.7%$1.51$1.23▼$9.42$40.60M1.174,729 shs101,225 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVRAnteris Technologies Global-1.81%+5.64%-13.19%+59.67%+486,999,900.00%LUCDLucid Diagnostics-4.07%+2.61%+10.28%+5.36%+45.68%SMTISanara MedTech-3.55%-5.36%-17.34%+7.41%-9.71%ZYXIZynex-0.75%-3.62%-11.33%-42.42%-83.14%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVRAnteris Technologies Global 2.60Moderate Buy$16.50238.81% UpsideLUCDLucid Diagnostics 2.67Moderate Buy$3.70213.56% UpsideSMTISanara MedTech 2.33Hold$50.0076.93% UpsideZYXIZynex 2.00Hold$4.90268.42% UpsideCurrent Analyst Ratings BreakdownLatest LUCD, SMTI, AVR, and ZYXI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025LUCDLucid DiagnosticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025AVRAnteris Technologies GlobalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025SMTISanara MedTechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025ZYXIZynexWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/6/2025LUCDLucid DiagnosticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.75 ➝ $8.009/27/2025AVRAnteris Technologies GlobalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025LUCDLucid DiagnosticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025SMTISanara MedTechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ZYXIZynexWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/5/2025LUCDLucid DiagnosticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$2.00 ➝ $2.508/18/2025SMTISanara MedTechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$53.00 ➝ $54.00(Data available from 10/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVRAnteris Technologies Global$2.48M70.84N/AN/A$1.74 per share2.80LUCDLucid Diagnostics$4.36M36.12N/AN/A($0.78) per share-1.51SMTISanara MedTech$86.67M2.90N/AN/A$4.45 per share6.35ZYXIZynex$192.35M0.21$0.24 per share5.49$1.12 per share1.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVRAnteris Technologies Global-$76.29MN/A0.00N/AN/AN/AN/AN/A11/10/2025 (Estimated)LUCDLucid Diagnostics-$45.53M-$1.19N/AN/AN/A-1,476.35%N/A-120.43%11/12/2025 (Estimated)SMTISanara MedTech-$9.66M-$1.16N/AN/AN/A-10.22%-26.43%-10.69%11/12/2025 (Estimated)ZYXIZynex$2.99M-$0.94N/A2.83N/A-19.79%-78.54%-16.70%10/30/2025 (Estimated)Latest LUCD, SMTI, AVR, and ZYXI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025LUCDLucid Diagnostics-$0.06N/AN/AN/A$1.35 millionN/A11/12/2025Q3 2025SMTISanara MedTech-$0.24N/AN/AN/A$26.63 millionN/A11/10/2025Q3 2025AVRAnteris Technologies Global-$0.5750N/AN/AN/A$0.74 millionN/A10/30/2025Q3 2025ZYXIZynex-$0.19N/AN/AN/A$22.71 millionN/A8/13/2025Q2 2025SMTISanara MedTech-$0.33-$0.23+$0.10-$0.23$25.15 million$25.83 million8/11/2025Q2 2025 TUAVRAnteris Technologies Global-$0.5333-$0.58-$0.0467-$0.58$0.58 million$0.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVRAnteris Technologies GlobalN/AN/AN/AN/AN/ALUCDLucid DiagnosticsN/AN/AN/AN/AN/ASMTISanara MedTechN/AN/AN/AN/AN/AZYXIZynexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVRAnteris Technologies GlobalN/A2.412.38LUCDLucid DiagnosticsN/A1.151.13SMTISanara MedTech1.252.262.03ZYXIZynex0.560.620.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVRAnteris Technologies GlobalN/ALUCDLucid Diagnostics74.01%SMTISanara MedTech8.10%ZYXIZynex29.68%Insider OwnershipCompanyInsider OwnershipAVRAnteris Technologies Global4.00%LUCDLucid Diagnostics6.80%SMTISanara MedTech42.60%ZYXIZynex49.28%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVRAnteris Technologies Global13836.06 million34.62 millionN/ALUCDLucid Diagnostics70133.48 million124.40 millionNo DataSMTISanara MedTech608.90 million5.11 millionNot OptionableZYXIZynex77030.30 million15.37 millionOptionableLUCD, SMTI, AVR, and ZYXI HeadlinesRecent News About These CompaniesAnalysts Offer Insights on Healthcare Companies: Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD) and Zynex (ZYXI)October 17 at 4:30 PM | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Zynex (ZYXI) and Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD)October 17 at 4:30 PM | theglobeandmail.comZynex appoints industry veteran Bret Wise to its Board, will also serve as Audit Committee chairOctober 15 at 8:22 AM | proactiveinvestors.comZynex Announces Appointment of Bret Wise to Board of Directors as Audit Committee ChairOctober 14, 2025 | prnewswire.comZynex's (ZYXI) Sell (D-) Rating Reiterated at Weiss RatingsOctober 11, 2025 | americanbankingnews.comZynex Seeks Partner for NiCO CO-Oximeter CommercializationOctober 7, 2025 | msn.comZYNEX INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Zynex, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmSeptember 27, 2025 | globenewswire.comZYNEX ALERT: Bragar Eagel & Squire, P.C. is Investigating Zynex, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmSeptember 9, 2025 | globenewswire.comZynex announces new executive teamAugust 18, 2025 | msn.comZynex welcomes Steve Dyson as CEO, adds to leadership teamAugust 18, 2025 | proactiveinvestors.comZynex Announces Arrival of Steven Dyson as CEO and Appointment of New Leadership in Key RolesAugust 18, 2025 | prnewswire.comZynex, Inc. Investors: Company Investigated by the Portnoy Law FirmAugust 14, 2025 | globenewswire.comZYNEX ALERT: Bragar Eagel & Squire, P.C. is Investigating Zynex, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmAugust 13, 2025 | globenewswire.comZynex Q2 Revenue Drops 55%August 5, 2025 | fool.comZynex Inc. Faces Challenges Amid Strategic ShiftsAugust 4, 2025 | theglobeandmail.comZynex, Inc. (NASDAQ:ZYXI) Q2 2025 Earnings Call TranscriptAugust 1, 2025 | msn.comHC Wainwright & Co. Downgrades Zynex (ZYXI)August 1, 2025 | msn.comZynex, Inc.: Zynex Reports Second Quarter 2025 Financial ResultsAugust 1, 2025 | finanznachrichten.deZynex Inc (ZYXI) Q2 2025 Earnings Report Preview: What to Look ForAugust 1, 2025 | finance.yahoo.comZynex, Inc. (ZYXI) Q2 2025 Earnings Call TranscriptJuly 31, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLUCD, SMTI, AVR, and ZYXI Company DescriptionsAnteris Technologies Global NASDAQ:AVR$4.87 -0.09 (-1.81%) As of 10/17/2025 04:00 PM EasternAnteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.Lucid Diagnostics NASDAQ:LUCD$1.18 -0.05 (-4.07%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$1.22 +0.04 (+2.97%) As of 10/17/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.Sanara MedTech NASDAQ:SMTI$28.26 -1.04 (-3.55%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$28.28 +0.01 (+0.05%) As of 10/17/2025 05:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.Zynex NASDAQ:ZYXI$1.33 -0.01 (-0.75%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$1.34 +0.00 (+0.38%) As of 10/17/2025 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
